Exscientia: Funding, Investors & Team (Sep 2026)

Exscientia is using artificial intelligence and big data processing to speed up the process of discovering and developing drugs. They are leading the way in the field of finding small molecule drugs. They have become the first company to automate drug design, surpassing the efforts of humans. Their AI-powered systems constantly learn from extensive databases of discovery information and also gain knowledge from experienced drug researchers. With access to more information than any individual researcher could gather, their systems create millions of new compounds tailored to specific projects and evaluate each compound for its predicted effectiveness, selectivity, ADME, and other important factors. The most promising compounds are then selected for synthesis and testing. With the generation of new experimental data, the results are analyzed and the next round of design begins. This rapid cycle of designing, making, and testing ensures remarkable progress towards the desired project objectives. Exscientia has already achieved remarkable productivity, delivering potential drug candidates in a fraction of the time compared to traditional methods.

Exscientia has raised $102M across 2 rounds on record. The most recent is an undisclosed round of $2.3M announced in Dec 2023.

Exscientia's most recent funding round on record is an undisclosed round of $2.3M, announced in Dec 2023.

Andrew Hopkins is listed as CEO at Exscientia.

Exscientia is based in Oxford, Oxfordshire, United Kingdom.

Exscientia is in the 251-500 employee band.

Exscientia's latest round of $2.3M is below the $5.5M median round size for Artificial Intelligence companies on FundedIQ across 7,233 tracked companies over the last two years.